Holen Sie sich die Stockscreener-App
16.87
13.07%
1.95
Vorhandelsmarkt:
16.90
0.03
+0.18%
Schlusskurs vom Vortag:
$14.92
Offen:
$16.74
24-Stunden-Volumen:
4.73M
Relative Volume:
3.31
Marktkapitalisierung:
$1.44B
Einnahmen:
$17.49M
Nettoeinkommen (Verlust:
$-78.50M
KGV:
-14.06
EPS:
-1.2
Netto-Cashflow:
$-52.85M
1W Leistung:
+9.90%
1M Leistung:
+6.57%
6M Leistung:
+50.22%
1J Leistung:
+31.08%
1-Tages-Spanne:
$15.95
$17.88
1-Wochen-Bereich:
$13.94
$17.88
52-Wochen-Spanne:
$8.26
$19.41
Liquidia Corp Stock (LQDA) Company Profile
Firmenname
Liquidia Corp
Sektor
Branche
Telefon
919.328.4400
Adresse
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Vergleichen Sie LQDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
16.87 | 1.33B | 17.49M | -78.50M | -52.85M | -1.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-19 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | Eingeleitet | Raymond James | Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Perform |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Underperform |
| 2022-09-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2022-07-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-05-31 | Eingeleitet | BTIG Research | Buy |
| 2022-05-26 | Eingeleitet | BofA Securities | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-05 | Eingeleitet | Wedbush | Outperform |
| 2018-08-20 | Eingeleitet | Jefferies | Buy |
| 2018-08-20 | Eingeleitet | Needham | Buy |
Alle ansehen
Liquidia Corp Aktie (LQDA) Neueste Nachrichten
Judge Denies UTC Bid To Block Liquidia's Lung Drug - Law360
BTIG raises Liquidia stock price target following FDA approval By Investing.com - Investing.com India
Raymond James maintains strong buy on Liquidia stock following court ruling - Investing.com India
BTIG raises Liquidia stock price target following FDA approval - Investing.com
Liquidia Beats UTC Bid to Block Launch of Lung Drug Yutrepia - Bloomberg Law News
Liquidia stock rises following YUTREPIA shipment news - Investing.com
Needham raises Liquidia Technologies stock price target after court ruling By Investing.com - Investing.com India
Liquidia (LQDA) Gets Price Target Boost from Needham | LQDA Stock News - GuruFocus
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension - marketscreener.com
Liquidia starts commercial shipment of FDA-approved YUTREPIA By Investing.com - Investing.com India
Liquidia (LQDA) Begins Commercial Launch of YUTREPIA Following L - GuruFocus
Liquidia starts commercial shipment of FDA-approved YUTREPIA - Investing.com
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - The Manila Times
Liquidia (LQDA) Stock Price Target Raised by Analyst | LQDA Stoc - GuruFocus
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
BTIG reaffirms buy rating for Liquidia stock amid legal developments - Investing.com
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - mx.advfn.com
Liquidia Told to Swap Two Defenses Ahead of Trial on UTC Patent - Bloomberg Law News
Wells Fargo lifts Liquidia stock price target to $23 from $20 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod By Investing.com - Investing.com South Africa
Scotiabank Raises Price Target for Liquidia (LQDA) to $37.00 | LQDA Stock News - GuruFocus
These Analysts Boost Their Forecasts On Liquidia - Benzinga
Scotiabank Increases Price Target for Liquidia (LQDA) After Yutrepia Approval | LQDA Stock News - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analy - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analyst | LQDA Stock News - GuruFocus
Liquidia Technologies stock target raised to $33 at Raymond James - Investing.com
Breaking Down Liquidia: 12 Analysts Share Their Views - Benzinga
Liquidia (LQDA) Price Target Raised to $35 by HC Wainwright | LQ - GuruFocus
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQ - GuruFocus
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch By Investing.com - Investing.com South Africa
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQDA Stock News - GuruFocus
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - The Globe and Mail
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | - GuruFocus
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | LQDA Stock News - GuruFocus
Needham Reiterates Buy Rating on LQDA with a Price Target of $25 - GuruFocus
Wells Fargo lifts Liquidia stock price target to $23 from $20 - Investing.com
Needham Reiterates Buy Rating on LQDA with a Price Target of $25.00 | LQDA Stock News - GuruFocus
BTIG raises Liquidia stock price target to $37, maintains buy - Investing.com
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQD - GuruFocus
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQDA Stock News - GuruFocus
Jefferies raises Liquidia Technologies stock target to $31 - Investing.com
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval - GuruFocus
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval | LQDA Stock News - GuruFocus
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept - marketscreener.com
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Transcript : Liquidia CorporationSpecial Call - marketscreener.com
BTIG maintains Liquidia stock Buy rating, $29 target - Investing.com
Raymond James maintains Strong Buy on Liquidia stock, $29 target - Investing.com
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod - MSN
Finanzdaten der Liquidia Corp-Aktie (LQDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):